Discovery Research, Cephalon, Inc., 145 Brandywine Parkway, West Chester, PA 19380, USA.
Bioorg Med Chem Lett. 2012 Jan 15;22(2):1073-7. doi: 10.1016/j.bmcl.2011.11.118. Epub 2011 Dec 4.
Optimization of the R(2) and R(6) positions of (5-{4-[3-(R)-2-methylpyrrolin-1-yl-propoxy]phenyl}-2H-pyridazin-3-one) 2a with constrained phenoxypiperidines led to the identification of 5-[4-(cyclobutyl-piperidin-4-yloxy)-phenyl]-6-methyl-2H-pyridazin-3-one 8b as a potent, selective histamine H(3) receptor antagonist with favorable pharmacokinetic properties. Compound 8b had an excellent safety genotoxocity profile for a CNS-active compound in the Ames and micronucleus tests, also displayed potent H(3)R antagonist activity in the brain in the rat dipsogenia model and robust wake activity in the rat EEG/EMG model.
(5-{4-[3-(R)-2-甲基吡咯烷-1-基-丙氧基]苯基}-2H-哒嗪-3-酮)2a 的 R(2)和 R(6)位与受约束的苯氧哌啶优化,导致鉴定出 5-[4-(环丁基-哌啶-4-基氧基)-苯基]-6-甲基-2H-哒嗪-3-酮 8b 作为一种有效的、选择性的组胺 H(3)受体拮抗剂,具有良好的药代动力学特性。化合物 8b 在 Ames 和微核试验中具有良好的安全性遗传毒性特征,对于中枢神经系统活性化合物来说,在大鼠诱发口渴模型中显示出很强的 H(3)R 拮抗剂活性,在大鼠 EEG/EMG 模型中显示出很强的唤醒活性。